{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:13:21Z","timestamp":1756383201343,"version":"3.40.4"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,9,18]]},"abstract":"<jats:p>The cancer immunotherapy field has had many promising developments in recent years. Checkpoint inhibitors are good examples of that. This new class of medications comes with a new constellation of side effects that require early recognition and management. Here we present a patient with metastatic adenocarcinoma on pembrolizumab who was admitted to the hospital for colitis. This was found to be an immune-related adverse event from pembrolizumab. We discuss our work-up and approach to the diagnosis, then highlight important treatment pearls for internal medicine physicians who are increasingly taking care of such patients.<\/jats:p>","DOI":"10.1136\/bcr-2017-221319","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T11:25:50Z","timestamp":1507116350000},"page":"bcr-2017-221319","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Unusual case of immune-related colitis"],"prefix":"10.1136","volume":"2017","author":[{"given":"Meltiady","family":"Issa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Milioglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2013-100316rep"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","volume":"35","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5306\/wjco.v8.i1.37","article-title":"From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1\/PD-L1 axis","volume":"8","author":"Bersanelli","year":"2017","journal-title":"World J Clin Oncol"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-017-0476-y","article-title":"Immune checkpoint inhibitor therapy: what line of therapy and how to choose?","volume":"18","author":"Ramamurthy","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0302"},{"key":"2025042712475082000_2017.oct03_1.bcr-2017-221319.10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-221319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T19:47:59Z","timestamp":1745783279000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-221319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":10,"alternative-id":["10.1136\/bcr-2017-221319"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-221319","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,10,4]]}}}